Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models

International Journal of Cancer

Volumn 135, Issue 12, 2014, Pages 2770-2782

  Fleuren, Emmy D G ^a   Versleijen Jonkers, Yvonne M H ^a   Roeffen, Melissa H S ^a   Franssen, Gerben M ^a   Flucke, Uta E ^a   Houghton, Peter J ^b   Oyen, Wim J G ^a   Boerman, Otto C ^a   Van Der Graaf, Winette T A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

18F FLT PET; Bevacizumab; Cisplatin; Osteosarcoma; Temsirolimus

Indexed keywords

2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CISPLATIN; FLUORODEOXYGLUCOSE F 18; MONOCLONAL ANTIBODY; MTOR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE; TEMSIROLIMUS;

ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; BONE NEOPLASMS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; DRUG SCREENING; FEMALE; HUMAN; METABOLISM; MOUSE; NUDE MOUSE; OSTEOSARCOMA; POSITRON EMISSION TOMOGRAPHY; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CELL LINE, TUMOR; CISPLATIN; DIDEOXYNUCLEOSIDES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; OSTEOSARCOMA; POSITRON-EMISSION TOMOGRAPHY; PROTEIN KINASE INHIBITORS; SIROLIMUS; TOMOGRAPHY, X-RAY COMPUTED; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84908680760     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28933     Document Type: Article

References (51)

1. Bielack S, Carrle D, Casali PG. Osteosarcoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20: 137-9.
2. Giamas G, Man YL, Hirner H, et al. Kinases as targets in the treatment of solid tumors. Cell Signal 2010;22:984-1002.
3. Martin DE, Hall MN. The expanding TOR signaling network. Curr Opin Cell Biol 2005;17: 158-66.
4. Wan XL, Helman LJ. The biology behind mTOR inhibition in sarcoma. Oncologist 2007;12: 1007-18.
5. Gazitt Y, Kolaparthi V, Moncada K, et al. Targeted therapy of human osteosarcoma with17AAG or rapamycin: characterization of induced apoptosis and inhibition of mTOR and Akt/ MAPK/Wnt pathways. Int J Oncol 2009;34:551- 61.
6. Moriceau G, Ory B, Mitrofan L, et al. Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (everolimus): pivotal role of the prenylation process. Cancer Res 2010;70:10329-39.
7. Zhou QA, Deng ZS, Zhu Y, et al. mTOR/p70S6K Signal transduction pathway contributes to osteosarcomaprogression and patients' prognosis. Med Oncol 2010;27:1239-45.
8. van de Luijtgaarden AC, Roeffen MH, Leus MA, et al. IGF signaling pathway analysis of osteosarcomas reveals the prognostic value of pAKT localization. Future Oncol 2013;9: 1733-40.
9. Blay JY. Updating progress in sarcoma therapy with mTOR inhibitors. Ann Oncol 2011;22:280-7.
10. Mita M, Sankhala K, bdel-Karim I, et al. Deforolimus (AP23573) a novel mTOR inhibitor in clinical development. Expert Opin Investig Drugs 2008;17:1947-54.
11. Houghton PJ, Morton CL, Kolb EA, et al. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 2008;50:799-805.
12. Mu X, Isaac C, Schott T, et al. Rapamycin inhibits ALDH activity, resistance to oxidative stress, and metastatic potential in murine osteosarcoma cells. Sarcoma 2013;2013:480713.
13. Wan XL, Mendoza A, Khanna C, et al. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res 2005;65:2406-11.
14. Chawla SP, Staddon AP, Baker LH, et al. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol 2012; 30:78-84.
15. Spunt SL, Grupp SA, Vik TA, et al. Phase I study of temsirolimus in pediatric patients with recurrent/ refractory solid tumors. J Clin Oncol 2011; 29:2933-40.
16. Wan XL, Shen N, Mendoza A, et al. CCl-779inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1 alpha/VEGF signaling. Neoplasia 2006;8:394-401.
17. van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, pla-cebo- controlled phase 3 trial. Lancet 2012;379: 1879-86.
18. Fleuren ED, Versleijen-Jonkers YM, Boerman OC, et al. Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: current hurdles and future perspectives. Biochim Biophys Acta 2014;1845:266-76.
19. van de Luijtgaarden AC, de Rooy JW, de Geus- Oei LF, et al. Promises and challenges of positron emission tomography for assessment of sarcoma in daily clinical practice. Cancer Imaging 2008;8: s61-s68.
20. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005;333:328-35.
21. Tajbakhsh M, Houghton PJ, Morton CL, et al. Initial testing of cisplatin by the pediatric preclinical testing program. Pediatr Blood Cancer 2008; 50:992-1000.
22. Fung AS, Wu LC, Tannock IF. Concurrent and sequential administration of chemotherapy and the mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts. Clin Cancer Res 2009;15:5389-95.
23. Heskamp S, Boerman OC, Molkenboer-Kuenen JD, et al. Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies. Int J Cancer 2013;133:307-14.
24. Houghton PJ, Morton CL, Gorlick R, et al. Stage 2 combination testing of rapamycin with cytotoxic agents by the pediatric preclinical testing program. Mol Cancer Ther 2010;9:101-12.
25. Shen C, Oswald D, Phelps D, et al. Regulation of FANCD2 by the mTOR pathway contributes to the resistance of cancer cells to DNA doublestrand breaks. Cancer Res 2013;73:3393-401.
26. Beuvink I, Boulay A, Fumagalli S, et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005;120:747- 59.
27. Overholtzer M, Rao PH, Favis R, et al. The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability. Proc Natl Acad Sci USA 2003;100:11547-52.
28. Fury MG, Sherman E, Ho AL, et al. A phase 1study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer. Cancer 2013;119:1823-31.
29. Sarkaria JN, Schwingler P, Schild SE, et al. Phase I trial of sirolimus combined with radiation and cisplatin in non-small cell lung cancer. J Thorac Oncol 2007;2:751-7.
30. Huynh H, Melissa CC, Soo KC. Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer. Mol Cancer Ther 2007;6:2959-66.
31. Huynh H, Chow PKH, Palanisamy N, et al. Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Hepatol 2008;49:52-60.
32. Alvarez EA, Brady WE, Walker JL, et al. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2013;129:22-7.
33. Cohen EEW, Sharma MR, Janisch L, et al. A phase I study of sirolimus and bevacizumab in patients with advanced malignancies. Eur J Cancer 2011;47:1484-9.
34. Negrier S, Gravis G, Perol D, et al. Temsirolimus and bevacizumab, #or |sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol 2011;12:673-80.
35. Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme. Anticancer Res 2013;33:1657-60.
36. Moroney J, Fu SQ, Moulder S, et al. Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity. Clin Cancer Res 2012;18:5796-805.
37. Moroney JW, Schlumbrecht MP, Helgason T, et al. A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies. Clin Cancer Res 2011;17:6840-6.
38. Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli Osteosarcoma-2 protocol: an updated report. J Clin Oncol 2000;18:4016-27.
39. Sleijfer S, Wiemer E, Verweij J. Drug Insight: gastrointestinal stromal tumors (GIST)-the solid tumor model for cancer-specific treatment. Nature Clin Pract Oncol 2008;5:102-11.
40. Desar IME, van Herpen CML, van Laarhoven HWM, et al. Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treat Rev 2009;35:309-21.
41. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005;23:7212-20.
42. Shi YF, Frankel A, Radvanyi LG, et al. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in-vitro. Cancer Res 1995;55:1982-8.
43. Wu CJ, Wangpaichitr M, Feun L, et al. Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Mol Cancer 2005;4.
44. Gupta M, Ansell SM, Novak AJ, et al. Inhibition of histone deacetylase overcomes rapamycinmediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. Blood 2009;114:2926-35.
45. Johnsen JI, Segerstrom L, Orrego A, et al. Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo. Oncogene 2008;27:2910-22.
46. Tabernero J, Rojo F, Calvo E, et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008;26:1603-10.
47. Aide N, Kinross K, Cullinane C, et al. 18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model. J Nucl Med 2010;51:1559-64.
48. Saint-Hubert MD, Brepoels L, Devos E, et al. Molecular imaging of therapy response with (18)F-FLT and (18)F-FDG following cyclophosphamide and mTOR inhibition. Am J Nucl Med Mol Imaging 2012;2:110-21.
49. McKinley ET, Ayers GD, Smith RA, et al. Limits of [F-18]-FLT PET as a biomarker of proliferation in oncology. PLoS One 2013;8.
50. Zhang CC, Yan ZM, Li WL, et al. [F-18] FLTPET imaging does not always "light up" proliferating tumor cells. Clin Cancer Res 2012;18:1303- 12.
51. Houghton PJ, Morton CL, Tucker C, et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer 2007;49:928-40.